MediWound: DSMB pass keeps the EscharEx readout on clock — but the stock is an option, not a re-rating

On the morning MediWound announced its independent safety board had cleared its most important drug trial to keep running, the stock fell about 4%. That gap between the headline and the tape is the whole story here, and it is worth a careful read for anyone watching MDWD.

MediWound is an Israeli biotechnology company that makes enzymatic therapies for tissue repair. It already sells one FDA-approved biologic, NexoBrid, used to dissolve dead tissue in thermal burns without surgery. The stock's value, though, rests far more on the next product: EscharEx, a bromelain-based therapy that removes dead tissue from chronic, hard-to-heal wounds like venous leg ulcers. That product's pivotal test is the Phase III "VALUE" trial, and it is the reason the shares trade around 13, near the bottom of a 52-week range between about 12.50 and 20.

What the safety board actually said

The Data and Safety Monitoring Board is the independent committee that watches a trial as it runs and can stop or change it if patients are being hurt or the study is a lost cause. On September 14, it recommended the VALUE study continue without modification, reporting it had not identified any safety concerns. The company framed that as consistent with the favorable safety record across the whole EscharEx program.

For the reader deciding whether this changes the investment case, the detail that matters most is what it does to the schedule. MediWound says the study's pre-specified interim analysis and the completion of patient enrollment are both expected by the end of the first quarter of 2027. That interim look happens after 65% of patients complete the 12-week treatment period, and it triggers a sample-size reassessment — effectively the trial's first real signal of whether the drug is working.

The design itself is worth understanding because it tells you how binary this bet is. VALUE is a randomized, double-blind, placebo-controlled trial with 216 venous leg ulcer patients split evenly between EscharEx and placebo across about 40 sites in the U.S., Europe, and Israel. There is no single clean answer: the trial has two co-primary endpoints, the incidence of complete debridement and the facilitation of wound closure. In plain terms, does the drug clear the wound bed, and does that translate into the wound healing shut? Both have to work for the product to reach a market the company now sizes at up to $1.05 billion in annual peak U.S. sales once pressure ulcers are folded in.

The good news is only table stakes

A clean safety pass is a real — but narrow — piece of progress. It removes one tail risk (the trial being halted for harm or bad design) and, more importantly, it keeps the interim readout on the calendar about six months out. That is what a catalyst clock needs.

It does not, however, tell the reader anything about whether EscharEx works. Safety reviews say nothing useful about efficacy, and efficacy is the entire question. So the piece of news that cleared today is the same kind of update biotechs hand out every few months — necessary, unexciting, and priced in. The stock sitting in the red on the announcement is largely the market agreeing that a "continue without modification" is the expected outcome, not a re-rating event.

Consider the arithmetic. MediWound has a market capitalization around $169 million. That entire number, on a company with roughly $12 million of trailing-twelve-month revenue, is a wager that the EscharEx trial succeeds. The trailing revenue multiple — about 14 times sales — is meaningless as a value anchor for a company losing money on a pre-commercial pivotal drug; the only honest way to read the $169 million is as the market's low probability that this binary trial comes through. A safety-board pass was always going to be consistent with that discount.

The funding clock is the live risk

Where the analysis gets uncomfortable is money. MediWound ended the first half of 2026 with about $36 million in cash, cash equivalents, and deposits — down from $54 million at the end of 2025 — and it burned roughly $20 million in the first half alone. Second-quarter revenue was $3.1 million, down from $5.7 million a year earlier, and gross margin collapsed to about 11% on a one-time facility scale-up charge. The company still guides to $24 million to $26 million of full-year 2026 revenue, but the first half delivered only about $4.6 million. That means essentially the entire year's revenue is expected in the back half, driven by milestone and government-funded programs rather than steady commercial sales, including expected second-half revenue from its Master Services Agreement with Vericel under Vericel's BARDA contract.

That backloaded profile has two consequences. First, it makes reported quarterly results look erratic — the $3.1 million quarter and the 14-times trailing multiple both owe more to when BARDA and Vericel development dollars land than to underlying demand. Second, it means the company must reach its interim readout at the end of Q1 2027 while the cash cushion is shrinking. On a roughly $10 million-per-quarter burn, the runway to the first real catalyst is doable, but it leaves little room for a slip in H2 revenue, and a full data readout and regulatory filing beyond the interim may require raising capital at whatever the market is then willing to pay — potentially a dilutive price if the trial disappoints.

None of this makes EscharEx a bad asset; it makes it an unpriced one. A $1.05 billion peak-sales opportunity sitting inside a $169 million shell including a real — if lumpy — commercial burn business is not obviously absurd. But the quality of the underlying drug and the quality of the stock are different questions, and today's news moved only the first. Clear it, continue, and the next honest decision point is that 65% interim look around the end of the first quarter of 2027, with the company's cash balance at that date determining how much of the eventual upside shareholders actually keep. The trade is not the safety board's rubber stamp; it is the efficacy readout and the funding runway that leads to it.